By Michael Jaasma, PhD, Co-founder and Chief Scientific Officer at Osteoboost Health In January 2024, Osteoboost achieved a notable regulatory milestone by receiving De Novo classification from the U.S. Food and Drug Administration (FDA). This designation is significant not only because FDA approval is a rigorous process but also because…
Read more
By Laura Yecies, CEO @Osteoboost Osteoporosis, a condition characterized by weakened bones and an increased risk of fractures, affects millions worldwide. While often perceived as predominantly impacting White populations, osteoporosis significantly affects Black individuals, who face unique challenges in diagnosis, treatment, and outcomes. In honor of Black History Month, it’s…
Read more
By Laura Yecies, CEO @ Osteoboost. It’s Friday at 5 p.m., and your coworkers are headed out for a few drinks to blow off steam. Or it’s Sunday afternoon and the carafe of mimosas is brought to the table. But you hesitate. Your doctor says you have osteopenia. What are…
Read more
By Michael Jaasma, PhD, Co-founder and Chief Scientific Officer at Osteoboost Health A few weeks ago, I was interviewed for an article in Women’s Health magazine about the pros and cons of weighted vests for improving bone health. I have seen several other articles and social media posts about weighted…
Read more
Almost four years ago, I had my second dexa scan and got the news that I have learned is typical: in the five years after menopause, my bone density went from normal to osteopenia. I lost 13% of my bone density in my spine. I got a weirdly chipper note…
Read more
REDWOOD CITY, CA (July 2, 2024) – Bone Health Technologies (BHT), a leading medtech innovator developing breakthrough noninvasive and drug-free solutions for low bone density, today announced the company has been awarded a fifth patent for Osteoboost—the first and only FDA-cleared prescription medical device to treat osteopenia. The patent, US…
Read more
Redwood City, CA – January 18, 2024 – Bone Health Technologies today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for OsteoboostTM, the first non-pharmacological device-based prescription treatment for postmenopausal women diagnosed with osteopenia (low bone density). Osteoboost is a wearable belt device, worn on the…
Read more
